Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Placenta extract shows promise for liver disease in early trial

NCT ID NCT05532124

Disease control Sponsor: Green Cross Wellbeing Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 2 trial tested LAENNEC, a substance made from human placenta, in 49 adults with chronic liver disease. The study aimed to check if the treatment is safe and whether it can improve liver function, measured by a drop in ALT levels. Participants received either LAENNEC or a placebo through an IV, and researchers compared side effects and ALT changes between the groups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LAENNEC (human placenta hydrolysate)
What this could lead to
If successful, this could point toward a new treatment option to improve liver health in people with chronic liver disease.
What could go wrong
This is a small, early-phase trial (Phase 2) with only 49 participants. The results may not apply to everyone, and the treatment may not prove effective in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

49 people

The number who actually took part.

Started

Jun 2021

Finished

Sep 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 74 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. At the time of screening, 18 or 75 years 2. Those who have been diagnosed with alcoholic or non -alcoholic fatty liver disease and have persisted for more than 6 months 3. Those who are 1.5 times (60 IU/L) of the ALT level of Baseline (60 IU/L) 4. A person who can complete the signature agreement and compliance the requirements for clinical trials. Exclusion Criteria: 1. Liver function abnormalities caused by the following cause disease: viral hepatitis, biliary obstructions, autoimmune hepatitis, wilson disease, hematoprive 2. Drug allergic symptoms (oscillation, heat, itching) 3. Those with systemic infection (including tuberculosis) 4. If the test person judges that it is difficult to participate in clinical trials due to the next disease: Cirrhosis of CHILD C or higher, cirrhosis with edema and plural, malignant tumors, severe disorders, severe renal disorders, severe cardiovascular disease, severe nerve Mental disorders, preferences, etc. 5. Those who have experienced use of human -derived medicines within 6 months before selecting a test subject 6. Those who have received other clinical drugs within 3 months before selecting a test subject 7. Magnetic Resonance Spectroscopy (MRS) is impossible 8. A person who does not perform appropriate contraception as a pregnant woman, a nursing or a woman of childbearing age (effective contraception method: Barrier methods using infertility surgery, uterine device, condom, killer) 9. Those who cannot inject intravenous infusions 10. Those who judged that other testors were inappropriate as clinical trials

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic liver disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic liver disease

Contacts and locations

Locations

  • Hanyang University Hospital.

    Seoul, South Korea

  • Keimyung university dongsan medical center

    Daegu, South Korea

  • Korea university guro hospital

    Seoul, South Korea

  • Severance hospital

    Seoul, South Korea

  • Soonchunhyang university hospital

    Seoul, South Korea

  • Wonju severance christian hospital

    Wŏnju, South Korea

  • Yeungnam university

    Daegu, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.